BLNP 018
Alternative Names: BLNP-018Latest Information Update: 28 Mar 2022
At a glance
- Originator BL-&-H
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis
- Discontinued Thromboangiitis obliterans
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Arthritis in South Korea
- 19 Feb 2019 Clinical trials in Arthritis in South Korea (unspecified route) (BL & H pipeline, February 2019)
- 17 Oct 2018 Discontinued - Preregistration for Thromboangiitis obliterans in South Korea (unspecified route)